Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03602261 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
A Phase 2 study, sponsored by OPKO Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT03602261 is a Phase 2 study that was terminated before completion, run by OPKO Health. The registered enrollment target is 44 participants.
The verdict
NCT03602261, a Phase 2 study, was terminated before completion, sponsored by OPKO Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
Interventions
- DRUG Placebo oral capsule
- DRUG Calcifediol Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-07-09 |
| Est. Completion | 2021-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03602261
The ClinicalTrials.gov registry entry for NCT03602261 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03602261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03602261 about?
NCT03602261 is a clinical study titled "Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI". Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
What is the current status of trial NCT03602261?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2018-07-09. Estimated completion is 2021-02-24.
What interventions are being tested in trial NCT03602261?
The interventions under investigation include: Placebo oral capsule (DRUG), Calcifediol Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT03602261?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.